Subsequently, in a subcutaneous transplantation tumor model using Foxp1-deficient LLC cells treated with anti-CD47 Ab, it was observed that Foxp1 deletion partially prevented the increase in the CTLA4 level induced by anti-CD47 Ab treatment. This evidence concerns the gene CTLA4 and neoplasm.